NovImmune masters three different, established and
validated technologies in house:
DiversityTrap platform: NovImmune's proprietary mAb generating platform enebling the selecton of fully human antibodies displayed on bacteriophages
The UltiMAb system to obtain fully human therapeutic monoclonal
antibodies using transgenic mice (technology licensed from Medarex),
Humanization, that is the grafting of the small
sequences responsible for the recognition and binding of the antigen from a
non-human species to a fully human mAb backbone
Therapeutic bispecific antibodies
NovImmune has developed a novel bispecific antibody format: the KL-body (kappa-lambda body)
The unique and competitive benefits of KL-Bodies:
Fully human IgG without alterations
Compatible with all modes of action enabled by bispecific antibodies
Immune cell retargeting to tumours
Dual inhibition
Increased killing specificity
CNS delivery
Intact Fc providing effector functions and extended half-life
Manufacturing and stability characteristics identical to standard monoclonal antibodies
